TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,691
Loading...
Loading...
News
all
press releases
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
Zacks·3mo ago
News Placeholder
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·3mo ago
News Placeholder
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Zacks·3mo ago
News Placeholder
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Zacks·4mo ago
News Placeholder
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
Zacks·4mo ago
News Placeholder
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
chainwire·5mo ago
News Placeholder
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary...
PR Newswire·7mo ago
News Placeholder
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takedas U.S. Business Unit, as the successor to...
Business Wire·8mo ago
News Placeholder
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch...
Business Wire·8mo ago

Latest TAK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.